Company Filing History:
1 out of 24 
1 out of 832,812 Years Active: 2012-2016
Title: Ralph Eberhard Graichen: Innovator in Cardiomyocyte Differentiation
Introduction
Ralph Eberhard Graichen is a notable inventor based in Singapore, SG. He has made significant contributions to the field of stem cell research, particularly in the differentiation of cardiomyocytes from embryonic stem cells. With a total of 2 patents, his work has the potential to impact regenerative medicine and cardiac therapies.
Latest Patents
Graichen's latest patents include innovative methods for the direct differentiation of cardiomyocytes from human embryonic stem cells. The first patent focuses on the induction of differentiation in human embryonic stem (hES) cells to cardiomyocytes, utilizing factors such as prostaglandin I2 (PGI2), Fgf 9, Bmp6, Bmp4, Scf, Igf2, and insulin. This invention also provides media suitable for the induction of differentiation, containing these critical factors. The second patent, titled "Prostacyclin Directed Differentiation of Cardiomyocytes from Human Embryonic Stem Cells," explores the use of prostaglandin and other essential minerals and growth factors to influence the differentiation process. This patent emphasizes the potential applications of the produced cardiomyocytes in transplantation and screening for cardiac compounds.
Career Highlights
Throughout his career, Graichen has worked with various organizations, including Es Cell International Pte Ltd. His expertise in stem cell technology and cardiomyocyte differentiation has positioned him as a key figure in this innovative field.
Collaborations
Graichen has collaborated with notable professionals such as Bruce Paul Davidson and Robert Zweigerdt. These partnerships have contributed to the advancement of his research and the development of his patents.
Conclusion
Ralph Eberhard Graichen's contributions to the field of cardiomyocyte differentiation highlight his innovative spirit and dedication to advancing medical science. His patents represent significant strides in stem cell research, with the potential to transform cardiac therapies.